{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:37:29Z","timestamp":1787827049622,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.clml.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T09:20:45Z","timestamp":1658049645000},"page":"e992-e999","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8509-6237","authenticated-orcid":false,"given":"Clayton P.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethel","family":"Adefres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Q.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-7486","authenticated-orcid":false,"given":"Neil","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Raldow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.07.005_bib0001","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1148\/96.3.619","article-title":"Physical and dosimetric aspects of the radiotherapy of malignant lymphomas","volume":"96","author":"Vera","year":"1970","journal-title":"Radiology"},{"key":"10.1016\/j.clml.2022.07.005_bib0002","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/bjc.1984.110","article-title":"A randomized study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: A report from the Manchester lymphoma group","volume":"49","author":"Anderson","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2022.07.005_bib0003","unstructured":"Thyroid Diseases after Treatment of Hodgkin's Disease | NEJM. Accessed February 8, 2021. Available at: https:\/\/www.nejm.org\/doi\/10.1056\/NEJM199108293250902?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed."},{"key":"10.1016\/j.clml.2022.07.005_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(03)01033-7","article-title":"Breast cancer in women after treatment for Hodgkin's disease","volume":"4","author":"Deniz","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0005","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2022.07.005_bib0006","doi-asserted-by":"crossref","unstructured":"Ferm\u00e9 C, Eghbali H, Meerwaldt JH, et\u00a0al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. doi:10.1056\/NEJMoa064601.","DOI":"10.1056\/NEJMoa064601"},{"key":"10.1016\/j.clml.2022.07.005_bib0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.005_bib0008","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European organization for research and treatment of cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0009","first-page":"1018","article-title":"PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease","volume":"43","author":"Kostakoglu","year":"2002","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.clml.2022.07.005_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.07.005_bib0011","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.07.005_bib0012","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography\u2013guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2249","article-title":"Cost-effectiveness of short-course radiation therapy vs. long-course chemoradiation for locally advanced rectal cancer","volume":"2","author":"Raldow","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clml.2022.07.005_bib0014","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1200\/JCO.2014.55.1150","article-title":"Value: a Framework for Radiation Oncology","volume":"32","author":"Teckie","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.07.005_bib0016","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3109\/10428194.2014.970542","article-title":"Health utilities in relation to treatment response and adverse events in relapsed\/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"56","author":"Swinburn","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.07.005_bib0017","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.15255","article-title":"Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes","volume":"182","author":"Parsons","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.07.005_bib0018","unstructured":"Your Medicare Coverage | Medicare. Accessed February 8, 2021. Available at: https:\/\/www.medicare.gov\/coverage."},{"key":"10.1016\/j.clml.2022.07.005_bib0019","first-page":"1","article-title":"U.S. organ and tissue transplants: Cost estimates, discussion, and emerging issues","author":"Bentley","year":"2020","journal-title":"Milliman Research Report"},{"key":"10.1016\/j.clml.2022.07.005_bib0020","series-title":"Decision Making in Health and Medicine: Integrating Evidence and Values","author":"Hunink","year":"2014"},{"key":"10.1016\/j.clml.2022.07.005_bib0021","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.prro.2021.11.010","article-title":"Is radiation therapy cost-effective in the positron emission tomography\/computed tomography era for early-stage favorable hodgkin lymphoma with alternative payment models?","volume":"12","author":"Kim","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0022","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0023","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0024","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for Hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2022.07.005_bib0025","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-156-11-201206050-00002","article-title":"Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study","volume":"156","author":"Henderson","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2022.07.005_bib0026","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ijrobp.2009.01.073","article-title":"Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy","volume":"75","author":"van den Belt-Dusebout","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022002270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:57Z","timestamp":1761871257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022002270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2152265022002270"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of PET Directed Versus Combined Modality Therapy for Early-Stage Favorable Hodgkin's Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}